<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364998</url>
  </required_header>
  <id_info>
    <org_study_id>19096</org_study_id>
    <secondary_id>2017-003201-18</secondary_id>
    <nct_id>NCT03364998</nct_id>
  </id_info>
  <brief_title>BAY94-9027 PK Study Comparing to Another Long Acting Product</brief_title>
  <official_title>Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics of BAY94-9027 and Elocta after
      intravenous administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Actual">September 28, 2018</completion_date>
  <primary_completion_date type="Actual">January 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each subject will receive the two treatments. Pharmacokinetic samples will be collected from pre-dose until 120 hours after the end of the injection of the single dose in each treatment arm.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC from time 0 to the last data point</measure>
    <time_frame>Pre-Dose and up to 120 hours post dose</time_frame>
    <description>Area under the concentration time profile curve.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>BAY94-9027 and Elocta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elocta and BAY94-9027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Damoctocog (Jivi, BAY94-9027)</intervention_name>
    <description>60 international units (IU)/kg, given as a 10 minute injection, 1 dose</description>
    <arm_group_label>BAY94-9027 and Elocta</arm_group_label>
    <arm_group_label>Elocta and BAY94-9027</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elocta</intervention_name>
    <description>60 IU/kg, given as a 10 minute injection, 1 dose</description>
    <arm_group_label>BAY94-9027 and Elocta</arm_group_label>
    <arm_group_label>Elocta and BAY94-9027</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males, age 18 to 65 years.

          -  Subjects with Severe Hemophilia A with a documented plasma FVIII level of &lt; 1%

          -  â‰¥ 150 exposure days with FVIII concentrate(s) as supported by medical records

        Exclusion Criteria:

          -  Evidence of current or past inhibitor antibody:

          -  History of any congenital or acquired coagulation disorders other than hemophilia A.

          -  Platelet count &lt;75,000/mm*3.

          -  Abnormal renal function (serum creatinine &gt;2 x the upper limit of the normal range).

          -  Active liver disease verified by medical history or persistently elevated alanine
             aminotransferase or aspartate aminotransferase &gt;5 x the upper limit of the normal
             range or severe liver disease as evidenced by, but not limited to any of the
             following: International Normalized Ratio &gt;1.4, hypoalbuminemia, portal vein
             hypertension including presence of otherwise unexplained splenomegaly and history of
             esophageal varices.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

